ASTRO Mark P Carol Radiation Theraphy

October 12, 2012 – The American Society for Radiation Oncology (ASTRO) has named Mark P. Carol, M.D., a distinguished leader in the fields of intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT), as its 2012 Honorary Member, which is the highest honor the society bestows upon distinguished cancer researchers and leaders in disciplines other than radiation oncology, radiation physics or radiobiology. Carol will be recognized with this honor during the Awards Ceremony on Tuesday, Oct. 30, 2012, at 10:45 a.m., at ASTRO’s 54th Annual Meeting, Oct. 28 to 31, 2012, at the Boston Convention and Exhibition Center.

With more than 30 years of experience in the medical device and health care services arenas, Carol is often considered the father of IMRT. Since 1992, he has developed and created many novel and crucial devices and techniques that have influenced and shaped modern radiation oncology, such as computed tomography (CT)/ magnetic resonance imaging (MRI) image fusion with ultrasound treatment room-based localization, intensity modulated treatment delivery, DVH-based prescriptions, simulated annealing optimization and image-guided therapy. Most recently, Carol has been developing an innovative way to deliver radiation therapy that uses a multiplexed photon beam to treat patients in sitting and standing positions, thereby reducing overall costs while at the same time allowing advanced multimodality imaging to be introduced seamlessly into the treatment room.

“Throughout the years, Carol, who trained as a neurosurgeon, has been a pioneer and innovator in the field of radiation oncology,” said Michael L. Steinberg, M.D., FASTRO, ASTRO president. “His groundbreaking approach to the development of IMRT and IGRT has provided tremendous benefits for radiation oncology patients. He is most deserving of this year’s honor.”

Serving as a founder, CEO and president for numerous corporations, Carol has constantly proven himself to be a successful innovator within the field of radiation oncology. He was awarded the Pittsburgh Business Times’ Health Care Hero Competition Award and the Ira Sohn Research Conference Prize in Pediatric Oncology from the Gotham Prize for Cancer Research. In 2004, Carol also garnered honorary membership in the American Association of Physicists in Medicine (AAPM).

Carol is a graduate of Amherst College in Amherst, Mass., as an independent scholar, and he graduated with distinction in research from the University of Rochester’s School of Medicine & Dentistry in Rochester, N.Y. At the University of Rochester, Carol worked on developing an artificial heart, for which he now holds a patent. From 1978-1984, he served as a neurosurgical resident and a fellow in neurotraumatology at the University of Maryland in College Park, M.D., and he later went on to practice at the Mary Imogene Bassett Hospital in Cooperstown, N.Y. He has also taught as an assistant professor of neurosurgery at Columbia University in New York, the University of South Florida in Tampa, Fla., and the Medical College of Ohio in Toledo, Ohio. Since 2009, Carol has been an adjunct assistant professor of radiation oncology at Brown University in Providence, R.I. He is currently the chief development officer at U.S. HIFU, an innovator in the use of high intensity focused ultrasound for thermal ablation, based in Charlotte, N.C.

For more information: www.astro.org


Related Content

News | Breast Imaging

September 27, 2023 — Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two ...

Time September 27, 2023
arrow
Feature | ASTRO | By Christine Book

September 26, 2023 — Ahead of the 65th American Society for Radiation Oncology Annual Meeting, ASTRO 2023, ITN’s ...

Time September 26, 2023
arrow
News | Prostate Cancer

September 22, 2023 — According to an accepted manuscript published in the American Journal of Roentgenology (AJR) ...

Time September 22, 2023
arrow
Feature | Radiation Oncology

The radiation oncology community lost a leader this past summer, with the passing of Jay Loeffler, MD, FACR, FASTRO. He ...

Time September 21, 2023
arrow
Feature | Proton Therapy | By Christine Book

An overview of significant developments in proton therapy, over just the past six months, reinforces the pace of ...

Time September 21, 2023
arrow
News | Radiation Therapy

September 20, 2023 — RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a ...

Time September 20, 2023
arrow
News | Radiation Oncology

September 6, 2023 — Nina D’Abreo, MD, has been named as chief of the Division of Hematology and Medical Oncology at NYU ...

Time September 06, 2023
arrow
News | Radiation Oncology

August 30, 2023 — Elekta and the IAEA have signed a partnership agreement to jointly pursue common interests, including ...

Time August 30, 2023
arrow
News | Radiopharmaceuticals and Tracers

August 28, 2023 — TerraPower Isotopes and PanTera, the Belgian joint venture created by SCK CEN and IBA, announced that ...

Time August 28, 2023
arrow
News | Radiology Business

July 27, 2023 — Privately-held biotech company TAE Life Sciences has announced that its board of directors has appointed ...

Time July 27, 2023
arrow
Subscribe Now